

Zhuang Tian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7726894/publications.pdf>

Version: 2024-02-01

64
papers

988
citations

471061

17
h-index

525886

27
g-index

79
all docs

79
docs citations

79
times ranked

1529
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 129.	0.7	94
2	Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China. <i>International Journal of Cardiology</i> , 2017, 236, 432-437.	0.8	81
3	The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2018, 20, 2.	1.6	68
4	Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. <i>European Respiratory Journal</i> , 2019, 53, 1800081.	3.1	49
5	Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2016, 15, 250-257.	2.5	45
6	Cisplatin-induced cardiotoxicity with midrange ejection fraction. <i>Medicine (United States)</i> , 2018, 97, e13807.	0.4	39
7	Anti-Endothelin Receptor Type A Autoantibodies in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatology</i> , 2015, 67, 2394-2402.	2.9	34
8	Association Between Subclinical Hypothyroidism and Blood Pressure - A Meta-Analysis of Observational Studies. <i>Endocrine Practice</i> , 2014, 20, 150-158.	1.1	32
9	Pathological Mechanisms and Potential Therapeutic Targets of Pulmonary Arterial Hypertension: A Review. , 2020, 11, 1623.		29
10	Pulmonary arterial hypertension associated with primary Sjögren's syndrome: a multicentre cohort study from China. <i>European Respiratory Journal</i> , 2020, 56, 1902157.	3.1	27
11	Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: Baseline characteristics and risk factors. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 921-928.	0.9	26
12	Assessment of cardiac amyloidosis with 99mTc-pyrophosphate (PYP) quantitative SPECT. <i>EJNMMI Physics</i> , 2021, 8, 3.	1.3	25
13	Regulation of Cell Cycle Regulators by SIRT1 Contributes to Resveratrol-Mediated Prevention of Pulmonary Arterial Hypertension. <i>BioMed Research International</i> , 2015, 2015, 1-14.	0.9	23
14	Clinical correlates and prognostic values of pseudoinfarction in cardiac light-chain amyloidosis. <i>Journal of Cardiology</i> , 2016, 68, 426-430.	0.8	23
15	Intracardiac thrombus in patients with Behçet's disease: clinical correlates, imaging features, and outcome: a retrospective, single-center experience. <i>Clinical Rheumatology</i> , 2016, 35, 2501-2507.	1.0	23
16	Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein. <i>Infection, Genetics and Evolution</i> , 2020, 85, 104419.	1.0	23
17	Predictive value of non-invasive right ventricle to pulmonary circulation coupling in systemic lupus erythematosus patients with pulmonary arterial hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 111-118.	0.5	22
18	Characteristics and risk factors of pulmonary arterial hypertension in patients with primary Sjögren's syndrome. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1068-1075.	0.9	21

#	ARTICLE	IF	CITATIONS
19	Red blood cell distribution width as a related factor of pulmonary arterial hypertension in patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2018, 37, 979-985.	1.0	19
20	CCL17 acts as a novel therapeutic target in pathological cardiac hypertrophy and heart failure. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	18
21	Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 66-73.	1.4	17
22	The LPS induced pyroptosis exacerbates BMPR2 signaling deficiency to potentiate SLE-PAH. <i>FASEB Journal</i> , 2021, 35, e22044.	0.2	15
23	Left and right ventricular myocardial deformation and late gadolinium enhancement: incremental prognostic value in amyloid light-chain amyloidosis. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 470-480.	0.7	14
24	Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 251.	1.2	13
25	Risk Factors and Prognostic Role of Left Atrial Enlargement in Patients with Cardiac Light-Chain Amyloidosis. <i>American Journal of the Medical Sciences</i> , 2016, 351, 271-278.	0.4	12
26	Transesophageal echocardiography to assess mitral valve movement and flow during long term cardiopulmonary resuscitation: How cardiac effects fade with time. <i>International Journal of Cardiology</i> , 2016, 223, 693-698.	0.8	11
27	Clinical characteristics in lymphangiomyomatosis-related pulmonary hypertension: an observation on 50 patients. <i>Frontiers of Medicine</i> , 2019, 13, 259-266.	1.5	11
28	Burnout and Well-Being Among Medical Professionals in China: A National Cross-Sectional Study. <i>Frontiers in Public Health</i> , 2021, 9, 761706.	1.3	11
29	Anomalous Origin of the Left Coronary Artery from the Pulmonary Artery Detected by Echocardiography in an Asymptomatic Adult. <i>Internal Medicine</i> , 2013, 52, 233-236.	0.3	10
30	Red blood cell distribution width as a potential predictor of survival of pulmonary arterial hypertension associated with primary Sjogren's syndrome: a retrospective cohort study. <i>Clinical Rheumatology</i> , 2019, 38, 477-485.	1.0	10
31	Inflammation in SLE-PAH: good news or not?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e135-e135.	0.5	10
32	Genomic profiling in amyloid light-chain amyloidosis reveals mutation profiles associated with overall survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 36-44.	1.4	10
33	Right Ventricular Function is Associated With Quality of Life in Patients With Systemic Lupus Erythematosus Associated Pulmonary Arterial Hypertension. <i>Heart Lung and Circulation</i> , 2019, 28, 1655-1663.	0.2	9
34	The Role of Anti-U1 RNP Positivity in Predicting Survival in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Angel or Demon? Comment on the Article by Sobanski et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 1788-1789.	2.9	8
35	Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy: A Single-Center Cohort Study of 227 Patients. <i>Circulation Journal</i> , 2019, 83, 775-782.	0.7	8
36	Predictive Value of Pulmonary Arterial Compliance in Systemic Lupus Erythematosus Patients With Pulmonary Arterial Hypertension. <i>Hypertension</i> , 2020, 76, 1161-1168.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, , .	0.7	8
38	Telangiectasia as a potential clinical marker of microvascular lesions in systemic sclerosis patients from EUSTAR data in China. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S106-10.	0.4	8
39	Optimal Oral Antithrombotic Regimes for Patients with Acute Coronary Syndrome: A Network Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e90986.	1.1	7
40	Predictors of health-related quality of life in patients with systemic lupus erythematosus associated pulmonary arterial hypertension. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 291-5.	0.4	7
41	Hemodynamic parameters obtained by transthoracic echocardiography and right heart catheterization: a comparative study in patients with pulmonary hypertension. <i>Chinese Medical Journal</i> , 2011, 124, 1796-801.	0.9	6
42	Successful Treatment of Type 1 Cryoglobulinemic Vasculitis With Cardiac Involvement. <i>Canadian Journal of Cardiology</i> , 2018, 34, 343.e1-343.e3.	0.8	5
43	Is it possible to apply the treat-to-target strategy in primary Sjögren's syndrome-associated pulmonary arterial hypertension?. <i>Clinical Rheumatology</i> , 2018, 37, 2989-2998.	1.0	5
44	Physicians' knowledge on specific rare diseases and its associated factors: a national cross-sectional study from China. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 120.	1.2	4
45	CBLN2 rs2217560 was Associated with Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus. <i>Chinese Medical Journal</i> , 2018, 131, 3020-3021.	0.9	3
46	Evaluating heart function in patients with POEMS syndrome. <i>Echocardiography</i> , 2019, 36, 1997-2003.	0.3	3
47	Establishment of an induced pluripotent stem cell line PUMChi004-A from a hereditary transthyretin amyloid cardiomyopathy patient with transthyretin (TTR) p.Asp38Asn mutation. <i>Stem Cell Research</i> , 2020, 49, 102022.	0.3	3
48	Validation of the REVEAL Prognostic Models in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension. <i>Frontiers in Medicine</i> , 2021, 8, 618486.	1.2	3
49	Prognostic Value of Circulating sST2 for the Prediction of Mortality in Patients With Cardiac Light-Chain Amyloidosis. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 597472.	1.1	3
50	Importance of endomyocardial biopsy in unexplained cardiomyopathy in China: a report of 53 consecutive patients. <i>Chinese Medical Journal</i> , 2010, 123, 864-70.	0.9	3
51	Disease Activity Is Related to Acute Response to Vasodilator in Pulmonary Artery Hypertension Associated With Systemic Lupus Erythematosus. <i>Circulation Journal</i> , 2014, 78, 1240-1244.	0.7	2
52	How should a physician approach the pharmacological management of chronic thromboembolic pulmonary hypertension?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 557-563.	0.9	2
53	Impact of pregnancy in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: case series and literature review. <i>Lupus Science and Medicine</i> , 2022, 9, e000636.	1.1	2
54	Recurrent Variant Angina Pectoris due to Behcet's Syndrome. <i>Internal Medicine</i> , 2011, 50, 2587-2589.	0.3	1

#	ARTICLE	IF	CITATIONS
55	Danon disease presenting as severe myocardial hypertrophy. <i>European Heart Journal</i> , 2011, 32, 2375-2375.	1.0	1
56	<i>Mycobacterium Avium</i> Spindle Cell Pseudotumor in the Left Ventricle. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e009604.	1.3	1
57	Right ventricular systolic function is associated with health-related quality of life: a cross-sectional study in community-dwelling populations. <i>Annals of Translational Medicine</i> , 2021, 9, 640-640.	0.7	1
58	Quality of life in ambulatory pulmonary arterial hypertension in connective tissue diseases and its relationship with risk stratification. <i>Pulmonary Circulation</i> , 2021, 11, 1-8.	0.8	1
59	A retrospective study of ultrahigh-risk (Mayo 2004 stage IIIb) AL amyloidosis and identification of predictors related to extremely early death. <i>Leukemia and Lymphoma</i> , 2022, 63, 1758-1761.	0.6	1
60	Preoperative immunosuppressive therapy reduces paravalvular leakage after aortic valve surgery in patients with aortic regurgitation attributable to Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S26-S33.	0.4	1
61	Infective Endocarditis in a Patient with Incomplete Shone's Anomaly. <i>Internal Medicine</i> , 2012, 51, 2835-2836.	0.3	0
62	Lymphoma in the heart:. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 830-830.	0.5	0
63	33€...Composite goals plus inflammation: further risk assessment for systemic lupus erythematosus associated pulmonary arterial hypertension in CSTAR-PAH cohort. , 2019, , .		0
64	Wild type transthyretin amyloidosis, a reason not to be forgotten for heart failure of preserved ejection fraction in the elderly. <i>Journal of Geriatric Cardiology</i> , 2020, 17, 793-796.	0.2	0